$74.00 / 10 Vials
PT-141 (Bremelanotide) is a synthetic peptide analog of α -MSH and a non-selective agonist of the melanocortin receptors. Unlike traditional phosphodiesterase-5 (PDE5) inhibitors that target the vascular system, PT-141 works directly through the central nervous system to stimulate sexual desire and arousal. It is widely utilized in clinical research for treating Hypoactive Sexual Desire Disorder (HSDD) and erectile dysfunction, offering a unique mechanism for cases that are unresponsive to conventional treatments.
Amino Acid Sequence
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Molecular Formula
$C_{50}H_{68}N_{14}O_{10}$
Molecular Weight
1025.2 g/mol
PubChem CID
9941329
CAS Number
189691-06-3
Vial Size
3ml (or standard 2ml/5ml vials)
Contents
Lyophilized powder, white/off-white color
| Size | 10mg |
|---|---|
| Mechanism of Action | Central Nervous System Activation: PT-141 binds to and activates Melanocortin Receptors (primarily MC3R and MC4R) in the hypothalamus, a region of the brain involved in sexual response and motivation. Independent of Blood Flow: Because its primary site of action is the brain, it can trigger arousal and desire even when local blood flow issues (which PDE5 inhibitors address) are not the primary cause. Dual-Gender Efficacy: Research models demonstrate increased sexual motivation and "proceptive" behavior in both male and female subjects. Rapid Onset: It is noted for its relatively fast biological response, typically manifesting within 2 to 4 hours in experimental settings. |
| Storage & handling | Storage:Store the lyophilized vial in a cool, dry area protected from direct sunlight. |
All products on this site are for laboratory research, development, or analytical use only; they are NOT FOR HUMAN CONSUMPTION, medical, diagnostic, cosmetic, or veterinary applications.
These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat, or prevent any disease. Genixpep is not a compounding or outsourcing facility under sections 503A/503B of the FD&C Act.
